Assembly Biosciences IncNASDAQ:ASMB
- LAST PRICE13.2700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots12.9000/ 6
- Ask / Lots14.2000/ 1
- Open / Previous Close0.0000 / 13.2700
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ASMB |
|---|---|---|
| 09:45 ET | 100 | 13.22 |
| 10:03 ET | 944 | 13.2 |
| 10:21 ET | 490 | 13.2 |
| 10:24 ET | 3445 | 13 |
| 10:28 ET | 100 | 13.19 |
| 10:37 ET | 200 | 13.18 |
| 10:50 ET | 200 | 13 |
| 11:09 ET | 2606 | 13.0097 |
| 12:03 ET | 300 | 13.02 |
| 02:33 ET | 100 | 13.19 |
| 02:36 ET | 1028 | 13.1 |
| 03:20 ET | 500 | 13.05 |
| 03:50 ET | 312 | 13.05 |
| 03:52 ET | 566 | 13.1644 |
| 03:57 ET | 100 | 13.05 |
| 03:59 ET | 103 | 13.27 |
Mar 28, 2024
Press Release: Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights, from 4:05PM ET on Thursday Mar 28, 2024 by Dow Jones
4:05PM ET on Thursday Mar 28, 2024 by Dow JonesAssembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights, from 4:05PM ET on Thursday Mar 28, 2024 by Dow Jones
4:05PM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Assembly Biosciences Inc | 72.8M | -0.9x | --- |
Calliditas Therapeutics AB | 549.5M | -11.3x | --- |
Incannex Healthcare Inc | 36.2M | -6.0x | --- |
Scorpius Holdings Inc | 5.8M | -0.1x | --- |
TherapeuticsMD Inc | 21.7M | -2.5x | --- |
Orexo AB | 52.9M | -4.2x | --- |
Company Information
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points with the aim of achieving finite treatment and functional cures and research programs focused on the discovery of therapeutics to treat devastating viral diseases, including a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-α (IFN-α) receptor (IFNAR) agonist targeting HBV and HDV. HPIs are antiviral agents in development for HSV-1 and HSV-2, with a clinically validated mechanism of action. Its HBV, HSV-1, and HSV-2 programs include ABI-6250, ABI-5366, and ABI-1179.
Contact Information
- Headquarters
- Two Tower Place, 7Th FloorSOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 212-554-4388
- Fax
- 646-706-5101
Executives
- Non-Executive Independent Chairman of the Board
- William Ringo
- President, Chief Executive Officer, Chief Operating Officer
- Jason Okazaki
- Chief Scientific Officer
- William Delaney
- Chief Medical Officer
- Anuj Gaggar
- Director
- Tomas Cihlar
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $72.8M |
|---|---|
Revenue (TTM) | $7.2M |
Shares Outstanding | 5.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.59 |
EPS | $-14.02 |
Book Value | $7.50 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 10.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -902.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
